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Tuberculosis (TB) remains a significant, yet under-recognized cause of death in the
pediatric population, with a WHO estimate of 1 million new cases of childhood TB in
2016 resulting in 250,000 deaths. Diagnosis is notoriously difficult; manifestations are
protean due to the high proportion of cases of extra-pulmonary TB in children, and
logistical problems exist in obtaining suitable specimens. These issues are compounded
by the paucibacillary nature of disease with the result that an estimated 96% of pediatric
TB-associated mortality occurs prior to commencing anti-tuberculous treatment. Further
development of sensitive, rapid diagnostic tests and their incorporation into diagnostic
algorithms is vital in this population, and central to the WHO End-TB strategy. Initial gains
were made with the expansion of nucleic acid amplification technology, particularly the
introduction of the GeneXpert fully-automated PCR Xpert MTB/Rif assay in 2010, and
more recently, the Xpert MTB/Rif Ultra (Ultra) assay in 2017. Ultra provides increased
analytical sensitivity when compared with the initial Xpert assay in vitro; a finding now
also supported by six clinical studies to date, two of which included pediatric samples.
Here, we review the published evidence for the performance of Ultra in TB diagnosis in
children, as well as studies in adults with paucibacillary disease providing results relevant
to the pediatric population. Following on from this, we speculate upon future directions
for Ultra, with focus on its potential use with alternative diagnostic specimens, which may
be of particular utility in children.
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BACKGROUND
Tuberculosis (TB) is currently the leading cause of mortality worldwide from a single infectious
agent, being responsible for an estimated 1.7 million deaths in 2016 (1). In childhood, more
than 96% of TB-related deaths are estimated to occur in children not receiving anti-tuberculous
treatment, highlighting significant challenges in diagnosis.
Atherton et al. Xpert Ultra in Childhood Tuberculosis
The often non-specific nature of TB presentation in children
has led to the development of a multitude of “scoring systems”
based on clinical assessment and basic investigations, with
most aimed at the diagnosis of pulmonary TB (2). However,
weaknesses exist within these diagnostic algorithms. Many rely
on the use of tuberculin skin testing, despite well-documented
limitations, particularly in endemic areas. In addition, chest
radiography is often recommended, but is difficult to interpret
in children, who often do not demonstrate “classic” radiological
findings indicative of TB (3). Due to the poor specificity
of diagnostic algorithms, estimates have shown that TB may
be both over-diagnosed and over-treated in some settings
(4); yet underdiagnosed in other settings. Mycobacteriological
diagnostics used in adults remain the “gold standard” but
demonstrate a lower sensitivity in children (5), both from
the paucibacillary nature of TB in children and the problem
obtaining adequate respiratory or non-respiratory specimens for
bacteriological confirmation (as young children are frequently
unable to voluntarily expectorate sputum) (6).
The development of rapid diagnostic TB tests is recognized
as a vital part of the WHO End TB Strategy (7), so as to allow
appropriate early initiation of TB treatment and thus reduce
mortality. Nucleic acid amplification tests have been available
since the 1990s, and offer increased speed of detection when
compared to mycobacterial culture, and increased sensitivity
when compared to sputum smear. However, early iterations
were costly and required a certain level of technical expertise
to operate, limiting their generalizability in less economically
developed settings.
GeneXpert® MTB/Rif
Introduction of the first-generation cartridge-based NAAT
GeneXpert R© MTB/Rif (Xpert) assay in 2010 heralded the start
of a revolution in TB diagnostics in low-resource settings.
This fully-automated system has the advantage that it may
be performed on-demand by personnel with minimal training
with a run time of approximately 2 hours. In 2011, the WHO
issued a strong recommendation for the use of Xpert assay
as the initial diagnostic test for sputum samples from patients
suspected of having pulmonary TB, to be used in preference
to conventional microscopy and culture (8), followed in 2013
by a recommendation for use with cerebrospinal fluid (CSF)
specimens from patients suspected of having TB meningitis (9),
as well as lymph nodes and other tissues.
Multiple studies have added to the early evidence for the
diagnostic accuracy of Xpert in pulmonary TB and rifampicin
resistance in children (10) and adults (11). A recent meta-analysis
of 15 studies (10), including 3,640 children, demonstrated a
sensitivity of Xpert for TB detection of 62% using expectorated
or induced sputum, and a sensitivity of 66% using samples
from gastric lavage. Although this represented a 36–44% higher
sensitivity when compared to smear microscopy, sensitivity
remains poor when compared to an adult population [for which
a recent Cochrane meta-analysis reported a pooled sensitivity of
89% for sputum Xpert (12)]. Indeed, one of the major recognized
limitations of Xpert is a reduced sensitivity amongst key groups,
including pediatric (10) and HIV-positive populations (12), due
to the paucibacillary nature of disease.
Xpert Ultra
In March 2017, following a multi-center non-inferiority study
at 10 sites in eight low- and middle-income countries (13),
Cepheid (with WHO approval) launched the second-generation
GeneXpert R© MTB/Rif Ultra (Ultra) assay (14, 15), with the
aim of further increasing sensitivity. Two significant changes
were made along with other technical optimizations. First, each
cartridge included a larger chamber for DNA amplification, thus
accommodating a larger-volume of sample proceeding forward
into the actual PCR reaction. Second, two additional molecular
targets forMycobacterium tuberculosiswere introduced, resulting
in a decrease in the limit of detection from ∼131 bacilli per ml
of sputum for Xpert to ∼16 for Ultra (15). Modifications were
made only within the cartridge, allowing Ultra cartridges to be
used with the pre-existing Xpert platform. The purchase price per
Ultra cartridge remains the same ($9.98) as the original Xpert for
countries eligible for concessional pricing.
We aimed to perform a mini-review and narrative of the
evidence to date for the performance of Ultra in TB diagnosis
in children, as well as studies in adults with paucibacillary disease
providing results relevant to the pediatric population, followed
by a commentary of future directions for Ultra.
MATERIALS AND METHODS
An electronic search was conducted with the aim of identifying all
papers evaluating the accuracy of Ultra on any clinical specimen
from adults or children with suspected tuberculosis. We searched
the PubMed and Cochrane Library electronic databases for
original studies and review articles published up to July 30, 2018,
using the search terms: Xpert ANDUltra AND (tubercul∗ OR tb).
We excluded articles with title and abstract in any language other
than English (0), and those for which we were unable to locate
the full text (0).
We reviewed 15 full texts (all PubMed) and included 6 for
discussion (13, 15–19) based on relevance of content to the
review question (Table 1). Of the included texts, two evaluated
the accuracy of Ultra for the diagnosis of pulmonary TB in the
pediatric population (16, 17). Four additional studies evaluated
Ultra in adult populations; (13, 15, 18, 19) with all including an
assessment of participants with paucibacillary disease, providing
further data relevant to a pediatric population.
EVIDENCE FOR USE OF ULTRA IN
CHILDREN
The WHO endorse the use of Xpert as the initial diagnostic test
in all children suspected of having TB, both for expectorated
sputum and samples obtained via gastric lavage (9).
Two accuracy studies of Ultra exist in a pediatric population.
The first was conducted by Nicol et al. (16), who retrospectively
analyzed banked induced sputum from 367 children under the
age of 15 years. Themedian age was∼3 years (interquartile range,
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1.25 to 6 years). Of 76 microbiologically-confirmed TB cases
using a composite reference standard of positive sputum Xpert,
Ultra, or culture, sensitivity of Xpert was 63% (48/76, 95%CI
51–74), and sensitivity of Ultra was 74% (56/76, 95%CI, 62–83),
representing an incremental benefit of 11%. Sensitivity of culture
was 83% compared to the composite reference standard.
Specificity of Ultra was 97% (225/233, 95%CI 93–99);
however, this rose to 100% when culture unconfirmed TB was
included. The authors therefore argue that the lower specificity
may represent misclassification of cases; indeed, the lower rate
of prior TB infection in children (8.5% of this population had
previously been treated for TB) likely decreases the number of
false positive results caused by residual M.tb DNA from prior
treated infection. Specificity of Ultra was lower in those who had
been previously treated for pulmonary TB (96%, 23/34, 95%CI
79–100) when compared to those who were treatment-naïve
(97%, 249/256, 95%CI 94–99), although not significantly so.
More recently, Sabi et al. (17) published the results of a
multicenter diagnostic accuracy study, which examined frozen
samples from 215 children across two sites in Tanzania, with a
median age of 5.4 years (interquartile range, 1.5 to 9.9 years),
and a higher HIV prevalence of 52%. 28 (13%) had culture-
confirmed tuberculosis; in these patients sensitivity of Ultra was
64% (18/28, 95%CI 44–81) and sensitivity of Xpert was 54%
(15/28, 95%CI 34–73) representing an 11% sensitivity increase
similar to that of Nicol et al. Of note, both the above studies were
retrospective, using cryopreserved sputum samples. Of the four
studies conducted in adults, two also used cryopreserved samples
(15, 19) whereas two were prospective (13, 18).
HIV Co-infection Sub-group Analysis
Xpert or Ultra are currently recommended as the first-line
investigation in all HIV-positive individuals, both adults and
children. Nicol et al. included a sub-group analysis of HIV-
positive children (N = 71) and reported a non-significant
difference in Ultra sensitivity in the HIV-positive (67%) and
HIV-negative (68%) populations. Sabi et al. also included a sub-
group analysis, albeit with a smaller cohort of nine HIV-positive
children, and reported a non-significant improvement (36%) in
Ultra sensitivity in this population, when compared to HIV-
negative children. When compared to the 19% improvement
in Xpert sensitivity, these results suggest a greater additional
diagnostic benefit for Ultra in the HIV-positive population, a
result mirrored in the adult population (13).
EVIDENCE FOR USE OF ULTRA IN ADULTS
WITH PAUCIBACILLARY DISEASE
Further support for the utility of Ultra in childrenmay be gleaned
from studies of other pauci-bacillary populations, including
smear-negative samples (13, 15, 19), as well as extra-pulmonary
specimens (18, 19) in adults.
Smear-Negative Pulmonary TB
Chakravorty et al. (15) performed a limited subgroup analysis
of Ultra on 109 smear-negative specimens, as part of a wider
assessment including 277 frozen sputum samples from a range
of geographical settings. Using a reference standard of sputum
culture, they demonstrated a sensitivity of Ultra for TB detection
of 79% (95%CI 70–86) compared with 66% (95%CI 56–75) for
Xpert in the smear-negative population.
Dorman et al. (13) also conducted a subgroup analysis using
137 smear-negative specimens, as part of a multicenter study in
which sputum from a large cohort of adults (25% HIV-positive)
with symptoms of pulmonary tuberculosis were evaluated using
smear, mycobacterial culture, Xpert, and Ultra. Sensitivity in the
smear-negative specimens was 63% (86/137, 95%CI 54–71) for
Ultra compared with 46% (63/137, 95%CI 37–55) for Xpert,
representing an increase of 17%. In comparison, across the whole
study population, sensitivity of Ultra was 5% superior to Xpert
(88 and 83% respectively) with both performing better than the
70% sputum smear sensitivity.
Dorman et al. also performed the most in-depth evaluation of
the specificity of Ultra to date. Across all patients, specificity was
lower for Ultra (96%; 934/977, 95%CI 94–97 compared to 98%;
960/977, 95%CI 97–99 in Xpert), an observation which may be
largely attributable to detection of residual DNA or non-viable
(non-culturable) M. tuberculosis bacilli from previously treated
antecedent TB infection. This is consistent with the observation
that specificity increased with increasing time since completion
of treatment. The group also reported semi-quantitative Ultra
results (including high, medium, low, very low, and a new “trace”
category not available with Xpert). 44% of participants with a
positive Ultra result had a “trace” result. Experts currently suggest
that in persons with prior TB, trace results require confirmation
by an alternative method.
Extra-Pulmonary TB
The use of Ultra is also supported for specimens from certain
patients suspected of having extrapulmonary TB, including
CSF, lymph node aspirates, and other tissue specimens (9).
For patients suspected of having TB meningitis, Ultra is
recommended as the initial diagnostic test (9, 18). Limited
evidence exists for use of Ultra and Xpert on other pauci-
bacillary specimens.
Bahr et al. evaluated 129 HIV-positive adults in Uganda with
suspected meningitis and assessed the performance of Xpert and
Ultra against a composite reference standard based on positive
CSF culture, Xpert, or Ultra (18). Amongst 22 patients with a
microbiological TB meningitis diagnosis, sensitivity of Ultra was
95% (21/22, 95%CI 77–99) compared with 45% (10/22, 95%CI
24–68) sensitivity for Xpert or for culture. Although Ultra has
a similar limit of detection in vitro as culture, Ultra has the
added advantage of being able to detect non-viable M.tb bacilli
in patients who have been initiated on anti-TB treatment in
the days prior to sample collection (15). In high TB burden
settings there can at times be a delay for several days, or even
weeks, in performing lumbar puncture and TB treatment may be
started whilst waiting for LP. In such cases molecular tests may
be positive whilst culture remains negative. Unlike in sputum
samples, false positivity of Ultra from residual M.tb DNA from
prior treated TB is unlikely to be an issue in CSF, a sterile bodily
fluid with high turnover, and TB meningitis usually only ever
strikes once in a lifetime.
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Further evaluation of Ultra sensitivity in extra-pulmonary
specimens by Perez-Risco et al. tested 108 banked culture-
positive, smear-negative specimens (19). HIV status was not
recorded. Perez-Risco calculated specificities for a wide range
of samples, both those already recommended by the WHO
for use in conjunction with Ultra, as well as those currently
not supported. Amongst supported specimens, sensitivity for
gastric aspirate was 75% (3/4), CSF 100% (3/3); lymph nodes
94% (16/17); and other tissues was 87% (13/15). Non-supported
extra-pulmonary samples were also tested. The sensitivities as
follows were for urine 100% (12/12), joint fluid 88% (7/8), stool
80% (4/5), pericardial fluid 67% (2/3), abscess aspirate 65%
(11/17), pleural fluid 48% (10/21), peritoneal fluid 33% (1/3) (19).
However, the lower sensitivity of the latter samples likely related
to the fact that only small aliquots were stored and tested. In
order to optimize performance of Xpert or Ultra, large volumes
should be concentrated by centrifugation (20). In testing 40
culture-negative samples and 20 non-tuberculous mycobacteria
samples, they demonstrated a specificity of 100% (19). Although
the numbers tested were small, the above study shows promise
for the utility of Ultra in pauci-bacillary specimens. Still no test
is 100% sensitive, including Ultra, thus a negative result cannot
definitively exclude TB.
THE FUTURE OF ULTRA IN PEDIATRIC TB
DIAGNOSIS
Over the past decade, significant advances have been made in TB
diagnostics, characterized largely by the expansion of automated
nucleic acid amplification technology to replace traditional
sputum microscopy. Currently, focus remains on improving
the technical performance of these tests, exemplified by the
introduction of Xpert MTB/RIF Ultra as the next-generation
Xpert, as well as expanding availability and faster turnaround
time for test results in rural areas. We have reviewed the existing
evidence regarding the accuracy of Ultra, with particular focus
on the use of Ultra in children. Limited research has also
been performed into improving the applicability of Xpert and
Ultra, with particular regard to the use of alternative diagnostic
specimens. However, further research is still required, and we
conclude this review with an outline of the potential future
directions for the use of Ultra in pediatric TB diagnosis, with a
selection of key studies to date.
Despite the high morbidity and mortality associated with
extra-pulmonary TB, most available tests are validated only for
use on sputum. The use of alternative diagnostic specimens
is of particular interest in the pediatric population, for whom
sputum samples are notoriously difficult to obtain, and for whom
extra-pulmonary disease constitutes approximately one-third of
cases (21). However, there exists a relative paucity of diagnostics
research using more easily available samples, such as urine, blood
or stool. In a survey of 91 pediatric TB experts based in Europe
in December 2017, 12.1% (n= 11) were already routinely testing
stool samples using PCR-based assays, and 40.6% (n = 37) were
routinely testing blood in suspected military TB, despite lack of
evidence (22).
Urine
Urine represents a clinical specimen that is both easily collectable
and available in large quantities, and is therefore theoretically
attractive as an extra-pulmonary sample for Ultra testing
Currently, in patients with suspected genitourinary/renal TB,
serial early-morning urine cultures are still considered the gold-
standard. However, studies have examined the potential for
using urine as a specimen for Xpert or Ultra in the diagnosis
of genitourinary TB. A meta-analysis of Xpert use on urine,
conducted across eight studies which included 725 specimens
from subjects of all ages, demonstrated 70% sensitivity and
94% specificity for genitourinary TB compared with a reference
standard of urine mycobacterial culture (23). As above, Perez-
Risco et al. found Ultra to be 100% sensitive for culture-positive
urine in adults (19), although patient numbers were small
(n= 12).
However, urine is likely to be of less use in the diagnosis of
pulmonary TB, as tuberculous bacilli must have disseminated to
the urinary tract to be present, which is usually more common
in immunocompromized patients (24). Whether Ultra could be
used on urine as a useful adjunctive diagnostic in disseminated
HIV-associated tuberculosis warrants investigation.
Blood
The use of blood as a diagnostic specimen in pulmonary TB
was evaluated in 44 HIV-positive adults with culture-positive
sputum, with sensitivities for both liquid blood culture and blood
Xpert reported as 21% (25). However, despite the low sensitivity
of blood Xpert for pulmonary TB, the authors note positivity
to be highly predictive of early mortality, with potential utility
for Xpert as a prognostic indicator, to aid in distinguishing
patients who may benefit from more intensive treatment or
immunomodulatory therapy.
Stool
Stool represents a more promising specimen for suspected
pulmonary TB, as M. tuberculosis may be present from
swallowed sputum. However, in a study of 37 children with
bacteriologically-confirmed TB, stool Xpert demonstrated a
sensitivity of only 29.7% although Xpert was superior to the
13.5% stool smear or 16.2% stool culture sensitivity (26). As
Ultra has an eight-fold lower limit of detection (∼15 CFU/ml
vs.∼100–120 CFU/ml for Xpert), Ultra may be a promising assay
for use on stool, which can be readily collected from any infant
mitigating the need for gastric aspirate. A recent evaluation of
Ultra showed a sensitivity of 80% amongst five stool culture-
positive adults (19); this certainly warrants further investigation
in the pediatric population.
Currently, Xpert is not recommended by the WHO using any
of the above samples, of urine, blood, or stool due to a lack
of adequate evidence (9). Further prospective evaluation of the
diagnostic performance of Ultra on non-respiratory specimens is
needed, particularly in the pediatric population.
Further work is also required in evaluating the performance
of Ultra alongside other innovative diagnostic tests, such as the
TB lipoarabinomannan (TB-LAM) lateral flow assay (Alere) and
a near future second-generation TB-LAM, and as part of the
diagnostic algorithms in a wide range of patient populations.
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Moreover, currently no evidence exists for the potential of novel
diagnostics to reduce morbidity or mortality in childhood TB
(27). Evaluation of the impact of Ultra in increasing diagnostic
yield, reducing time to treatment initiation and improving
outcomes, will be helpful programatically. Finally, previous
studies which have performed cost-benefit analysis of Xpert
(28), both in low-burden and high-burden countries (29–32);
should be replicated for Ultra, across different geographical and
economic settings.
CONCLUSIONS
TB still poses significant diagnostic challenges in children, and
the development of further diagnostic options is essential in
reducing mortality and morbidity from this condition. Ultra
represents the most recent advancement in molecular diagnostics
and is recommended by theWHO for the diagnosis of pulmonary
TB in children, in conjunction with sputum or gastric aspirate
samples. Ultra boasts increased sensitivity compared to its
predecessor Xpert, with particular gains demonstrated pauci-
bacillary populations. The slight reduction in specificity seen in
adult studies with previously treated TB is less likely to represent
a problem in TB-naïve pediatric populations. A challenge in
children remains the difficulty obtaining suitable diagnostic
specimens. Studies have shown potential for use of Ultra
in alternative samples, particularly stool. Further prospective
evaluation is required.
AUTHOR CONTRIBUTIONS
DB devised the review, the main conceptual ideas, and proof
outline. RA drafted the manuscript and FC, JE, SK, and
DB revised the manuscript critically for important intellectual
content. All authors approved of the version of the manuscript
to be published.
ACKNOWLEDGMENTS
FC is an honorary fellow of the Makerere University—Uganda
Virus Research Institute Center of Excellence for Infection and
Immunity Research and Training (MUII-plus). MUII-plus is
supported through the DELTAS Africa Initiative (Grant no.
107743). TheDELTASAfrica Initiative is an independent funding
scheme of the African Academy of Sciences (AAS), Alliance
for Accelerating Excellence in Science in Africa (AESA), and
supported by the New Partnership for Africa’s Development
Planning and Coordinating Agency (NEPAD Agency) with
funding from theWellcome Trust (Grant no. 107743) and the UK
Government. DB is supported byNational Institute of Neurologic
Diseases and Stroke (R01 NS086312).
REFERENCES
1. WHO. Global Tuberculosis Report 2017. (2017).
2. Hesseling AC, Schaaf HS, Gie RP, Starke JR, Beyers N. A critical review of
diagnostic approaches used in the diagnosis of childhood tuberculosis. Int J
Tuberc Lung Dis. (2002) 6:1038–45.
3. Kim WS, Choi JI, Cheon JE, Kim IO, Yeon KM, Lee HJ. Pulmonary
tuberculosis in infants: radiographic and CT findings. AJR Am J Roentgenol.
(2006) 187:1024–33. doi: 10.2214/AJR.04.0751
4. Schumacher SG, van Smeden M, Dendukuri N, Joseph L, Nicol MP, Pai
M, et al. Diagnostic test accuracy in childhood pulmonary tuberculosis:
a Bayesian latent class analysis. Am J Epidemiol. (2016) 184:690–700.
doi: 10.1093/aje/kww094
5. Kunkel A, Abel Zur Wiesch P, Nathavitharana RR, Marx FM, Jenkins
HE, Cohen T. Smear positivity in paediatric and adult tuberculosis:
systematic review and meta-analysis. BMC Infect Dis. (2016) 16:282.
doi: 10.1186/s12879-016-1617-9
6. Marais BJ, Graham SM. Childhood tuberculosis: a roadmap towards zero
deaths. J Paediatr Child Health. (2016) 52:258–61. doi: 10.1111/jpc.12647
7. WHO. The End TB Strategy. WHO (2015).
8. WHO. Automated Real-time Nucleic Acid Amplification Technology for Rapid
and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert
MTB/RIF System: Policy Statement. Geneva: World Health Organization
(2011).
9. WHO. Policy Update: Xpert MTB/RIF Assay for the Diagnosis of Pulmonary
and Extrapulmonary TB in Adults and Children (2014). Geneva.
10. Detjen AK, DiNardo AR, Leyden J, Steingart KR, Menzies D, Schiller I, et al.
Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children:
a systematic review and meta-analysis. Lancet Respir Med. (2015) 3:451–61.
doi: 10.1016/S2213-2600(15)00095-8
11. Kaur R, Kachroo K, Sharma JK, Vatturi SM, Dang A. Diagnostic accuracy of
Xpert test in tuberculosis detection: a systematic review and meta-analysis. J
Global Infect Dis. (2016) 8:32–40. doi: 10.4103/0974-777X.176143
12. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri
N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin
resistance in adults. Cochrane Database Syst Rev. (2014) Cd009593.
doi: 10.1002/14651858.CD009593
13. Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B,
et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and
rifampicin resistance: a prospective multicentre diagnostic accuracy study.
Lancet Infect Dis. (2018) 18:76–84. doi: 10.1016/S1473-3099(17)30691-6
14. Cepheid. 2017 launch of new TB test Ultra backed by WHO recommendation.
(2017).
15. Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, et al.
The new xpert MTB/RIF ultra: improving detection of mycobacterium
tuberculosis and resistance to rifampin in an assay suitable for
point-of-care testing. mBio (2017) 8:e00812-17. doi: 10.1128/mBio.00
812-17
16. Nicol MP, Workman L, Prins M, Bateman L, Ghebrekristos Y, Mbhele S,
et al. Accuracy of xpert MTB/RIF ultra for the diagnosis of pulmonary
tuberculosis in children. Pediatr Infect Dis J. (2018) 37:e261–3.
doi: 10.1097/INF.0000000000001960
17. Sabi I, Rachow A, Mapamba D, Clowes P, Ntinginya NE, Sasamalo M, et al.
Xpert MTB/RIF Ultra assay for the diagnosis of pulmonary tuberculosis in
children: a multicentre comparative accuracy study. J Infect. (2018) 77:321–7.
doi: 10.1016/j.jinf.2018.07.002
18. Bahr NC, Nuwagira E, Evans EE, Cresswell FV, Bystrom PV, Byamukama A,
et al. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis
in HIV-infected adults: a prospective cohort study. Lancet Infect Dis. (2018)
18:68–75. doi: 10.1016/S1473-3099(17)30474-7
19. Perez-Risco D, Rodriguez-Temporal D, Valledor-Sanchez I, Alcaide F.
Evaluation of the Xpert MTB/RIF ultra assay for direct detection of
Mycobacterium tuberculosis complex in smear-negative extrapulmonary
samples. J Clin Microbiol. (2018) 56:e00659–18. doi: 10.1128/JCM.00659-18
20. Bahr NC, Tugume L, Rajasingham R, Kiggundu R,Williams DA, Morawski B,
et al. Improved diagnostic sensitivity for tuberculous meningitis with Xpert R©
MTB/RIF of centrifuged CSF. Int J Tuberc Lung Dis. (2015) 19:1209–15.
doi: 10.5588/ijtld.15.0253
21. Kyu HH, Maddison E, Henry N, Mumford JE, Barber RM, Shields
C, et al. The global burden of tuberculosis: results from the Global
Frontiers in Pediatrics | www.frontiersin.org 6 February 2019 | Volume 7 | Article 34
Atherton et al. Xpert Ultra in Childhood Tuberculosis
Burden of disease study 2015. Lancet Infect Dis. (2018) 18:261–84.
doi: 10.1016/S1473-3099(17)30703-X
22. Villanueva P, Neth O, Ritz N, Tebruegge M. Use of Xpert MTB/RIF Ultra
assays among paediatric tuberculosis experts in Europe. Eur Respir J. (2018)
51:1800346. doi: 10.1183/13993003.00346-2018
23. Penz E, Boffa J, Roberts DJ, Fisher D, Cooper R, Ronksley PE, et al.
Diagnostic accuracy of the Xpert(R) MTB/RIF assay for extra-pulmonary
tuberculosis: a meta-analysis. Int J Tuberc Lung Dis. (2015) 19:278–84, i–iii.
doi: 10.5588/ijtld.14.0262
24. Lawn SD, Gupta-Wright A. Detection of lipoarabinomannan (LAM) in urine
is indicative of disseminated TB with renal involvement in patients living with
HIV and advanced immunodeficiency: evidence and implications. Trans R Soc
Trop Med Hyg. (2016) 110:180–5. doi: 10.1093/trstmh/trw008
25. Feasey NA, Banada PP, Howson W, Sloan DJ, Mdolo A, Boehme C,
et al. Evaluation of Xpert MTB/RIF for detection of tuberculosis from
blood samples of HIV-infected adults confirms Mycobacterium tuberculosis
bacteremia as an indicator of poor prognosis. J ClinMicrobiol. (2013) 51:2311–
6. doi: 10.1128/JCM.00330-13
26. Walters E, Demers AM, van der Zalm MM, Whitelaw A, Palmer M, Bosch C,
et al. Stool culture for diagnosis of pulmonary tuberculosis in children. J Clin
Microbiol. (2017) 55:3355–65. doi: 10.1128/JCM.00801-17
27. Auld AF, Fielding KL, Gupta-Wright A, Lawn SD. Xpert MTB/RIF — why
the lack of morbidity and mortality impact in intervention trials? Trans R Soc
Trop Med Hyg. (2016) 110:432–44. doi: 10.1093/trstmh/trw056
28. Pantoja A, Fitzpatrick C, Vassall A, Weyer K, Floyd K. Xpert
MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis:
a cost and affordability analysis. Eur Respir J. (2013) 42:708–20.
doi: 10.1183/09031936.00147912
29. Langley I, Lin HH, Egwaga S, Doulla B, Ku CC, Murray M, et al.
Assessment of the patient, health system, and population effects of Xpert
MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an
integrated modelling approach. Lancet Global Health (2014) 2:e581–91.
doi: 10.1016/S2214-109X(14)70291-8
30. Pinto M, Steffen RE, Cobelens F, van den Hof S, Entringer A, Trajman A.
Cost-effectiveness of the Xpert(R) MTB/RIF assay for tuberculosis diagnosis
in Brazil. Int J Tuberc Lung Dis. (2016) 20:611–8. doi: 10.5588/ijtld.15.0455
31. Vassall A, Siapka M, Foster N, Cunnama L, Ramma L, Fielding K, et al. Cost-
effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a
real-world cost analysis and economic evaluation. Lancet Global Health (2017)
5:e710–e9. doi: 10.1016/S2214-109X(17)30205-X
32. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S,
et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high
burden countries: a cost-effectiveness analysis. PLoS Med. (2011) 8:e1001120.
doi: 10.1371/journal.pmed.1001120
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Atherton, Cresswell, Ellis, Kitaka and Boulware. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Pediatrics | www.frontiersin.org 7 February 2019 | Volume 7 | Article 34
